U.S. Markets open in 8 hrs 44 mins

Shire plc (SHPG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
185.35+0.36 (+0.19%)
At close: 4:00PM EDT
People also watch
JAZZALXNBMRNREGNBAX
Interactive chart
Previous Close184.99
Open184.15
Bid160.15 x 100
Ask192.00 x 1000
Day's Range183.83 - 186.06
52 Week Range161.09 - 209.22
Volume844,819
Avg. Volume991,237
Market Cap55.34B
Beta1.72
PE Ratio (TTM)190.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.91 (0.49%)
Ex-Dividend Date2017-03-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • Ultragenyx Receives Priority Review for rhGUS from FDA
    Zacks15 hours ago

    Ultragenyx Receives Priority Review for rhGUS from FDA

    The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

  • American City Business Journals2 days ago

    Shire and tiny Lexington biotech say hemophilia drug trial misses mark

    Shares of Xenetic Biosciences sank on Monday after the Lexington biotech announced a significant setback in its collaboration with Shire plc on a hemophilia drug. Xenetic (XBIO), which has seven employees, announced disappointing results from a Phase 1/2 study of Shire’s SHP656 hemophilia A treatment using Xenetic’s PolyXen technology, which is designed to extend the half-life of drugs. While the technology did extend the half-life of SHP656, and there were no major side effects, Xenetic said the trial had missed its goal of enabling once-weekly dosing.

  • Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
    Zacks5 days ago

    Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

    Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.